Eisai is concentrating its six types of capital, including human and intellectual capital, in the three areas of dementia, oncology, and global health. Additionally, to maximize our social impact and financial value, we are prioritizing efforts to address 15 material topics. By delivering the drugs and solutions created through these activities, we aim to effectively realize social good by relieving anxiety over health and reducing health disparities. Using this business model, our mission is to increase the satisfaction of patients and the people in the daily living domain, leading to the creation of financial value and the enhancement of these six types of capital. We envisage that this will result in sustainable corporate value creation and an increase in our price-to-book value ratio (PBR). We will create social impact by continuing sustainable efforts to realize our corporate concept, then reinvesting capital to further expand our social impact. This is Eisai’s social impact creation model.
